SV Health Investors のニュースと活動

SV Health Investors は 2 の国に直接拠点を置いています。

66人の主要幹部と一緒に組織図を見る

SV Health Investorsでもっとも検索された略歴

• Eugene Hill, Chairman of the Board
• Paul LaViolette, Managing Partner, Medical Technology and Chief Op...
• Greg Madden, Managing Partner, Medtech and Healthcare Growth

更新履歴 - ％sの

• Miles Gersonは、Partner, Therapeuticsとして加わりました (2026年3月24日公開されたニュース).

アラートを作成
SV Health Investors のエグゼクティブの異動をフォローします。

SV Health InvestorsはBlackRock (アメリカ合衆国（米国）),KKR (アメリカ合衆国（米国）),Blackstone Group (アメリカ合衆国（米国）)を含む1,667の競合企業を有します。

Popular M&A news in ファンド

• ％2$sは％1 $ sを取得しました (2026年7月22日に公開).
• Lone Star Funds has announced the acquisition of ContiTech  (2026年7月17日に公開).
• ％2$sは％1 $ sを取得しました (2026年7月14日に公開).

ファンド業界でのその他のコンタクトの提案

• Valor Equity Partners 社 Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer
• General Catalyst Partners 社 Hemant Taneja - Chief Executive Officer and Managing Director
• Vanguard 社 Salim Ramji - Chief Executive Officer and Director

ファンド業界についてさらに知る

％sによる最新のプレスリリース

• AdvanCell Closes US $315 Million Oversubscribed Series D Financing to Advance Targeted Alpha Therapies and Expand Clinical and Commercial Manufacturing Infrastructure - SV Health Investors
• Draig Therapeutics Closes Oversubscribed $65 Million Series B to Accelerate Development of Highly Specific AMPA and GABAA Receptor Modulators in Neuropsychiatric Disorders - SV Health Investors
• Prilenia and Ferrer Announce Initiation of the Confirmatory PRECISE-HD Study of Pridopidine in Huntington’s Disease - SV Health Investors
• Alchemab Therapeutics announce biggest ever life sciences investment from British Business Bank to advance its AI-enabled clinical pipeline of next generation human-derived antibodies - SV Health Investors
• Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial - SV Health Investors
• Artios Announces First Patient Dosed in Randomized Phase 2 POLKA Study Evaluating DNA Polymerase Theta Inhibitor ART6043 in gBRCA-mutated HER2-Negative Breast Cancer - SV Health Investors
• Prilenia Donates Clinical Trial Datasets to CHDI Foundation to Advance Huntington's Disease Research - SV Health Investors
• AviadoBio Announces Agreement with Apertura Gene Therapy to License TfR1 CapX™, a Next-Generation Blood-Brain Barrier-Crossing Capsid - SV Health Investors
• AviadoBio Advances AVB-101 Gene Therapy Program and Initiates Fourth Dose-Escalation Cohort of Phase 1/2 ASPIRE-FTD Trial - SV Health Investors
• Leal Therapeutics Announces Executive Leadership Appointments and Provides Business Update - SV Health Investors
• View more press releases Close

％sについてのソーシャルメディア

• SV Health Investors についてのウィキペディア,Google News & Yahoo Financeの記事
• SV Health Investors についてのLinkedIn,ツイッター & YouTubeの記事